Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN-101 Phase 1b in Obesity
NCT06417697Phase 1Terminated
- Sponsor
- Xeno Biosciences
- Start
- May 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing XEN-101 with Placebo (2 arms). Primary endpoints: Incidence of treatment emergent adverse events and Effect on body weight. Started May 2024; status: terminated.
02
Drugs
XEN-101
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06417697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417697.